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The incidence of pertussis has been greatly
reduced by mass vaccination; however, even in
countries with high vaccination coverage, the
disease is reemerging (1-4). A sudden increase in
cases reflecting a pertussis outbreak in the
Netherlands in 1996 (5) could not be explained by
a decrease in vaccination coverage, which
remained stable at 96% for at least three
vaccinations in the first year of life. Until
January 1999, children were vaccinated at 3, 4, 5,
and 11 months of age with a diphtheria, tetanus,
pertussis, and inactivated polio vaccine. In 1999,
the schedule changed, and vaccine was adminis-
tered at 2, 3, 4, and 11 months of age. The vaccine
used meets international standards; no sign of an
abrupt or gradual deterioration of vaccine
quality, as determined at product release by the
mouse protection test, was found. The introduc-
tion of vaccination against Haemophilus
influenzae type b in 1993 did not interfere with
the immunoresponse to pertussis (6), and no
cohort effect in children vaccinated for
H. influenzae type b was observed (5). A
mismatch between the vaccine and circulating
strains of Bordetella pertussis (5,7-9) may have
contributed to pertussis reemergence.
Determining the epidemiology of pertussis by
case-reporting data is hampered by changes in
case definitions, availability and interpretation
of laboratory diagnostic tests, case-reporting
rates, and diagnostic practice. To ascertain the
current epidemiology of pertussis in the
Netherlands and to try to determine the cause of
the 1996 epidemic, we compared case-reporting
data from January 1976 to September 1998 with
other surveillance data (deaths, hospitalizations,
and positive serodiagnoses).
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We analyzed pertussis reporting, death, hospitalization, and serodiagnostic data
from 1976 to 1998 to help explain the cause of the 1996 pertussis outbreak in the
Netherlands. The unexpected outbreak was detected by an increase in pertussis
reporting and by other surveillance methods. In 1996, according to reporting and
serologic data, the increase in pertussis incidence among (mostly unvaccinated)
children less than 1 year of age was similar to the increase in hospital admissions.
Among older (mostly vaccinated) persons, the increase in hospital admissions was
relatively small. The increase in pertussis incidence was higher among vaccinated
than among unvaccinated persons of all ages. This resulted in lower estimates of
vaccine effectiveness. The proportion of pertussis infections resulting in recognizable
symptoms may have increased among vaccinated persons because of a mismatch of
the vaccine strain and circulating Bordetella pertussis strains. The small
immunogenicity profile of the Dutch vaccine may have resulted in greater vulnerability
to antigenic changes in B. pertussis.Research
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Methods
Surveillance Data
Case Reporting
Data from pertussis reporting (required by
law since 1976) were obtained from 1976 to 1998
from the Inspectorate of Health. A case
definition, introduced in 1988, included clinical
symptoms and laboratory confirmation (or close
contact with a person with laboratory-confirmed
pertussis). The clinical symptoms are a serious
cough >2 weeks, coughing attacks, or coughing
followed by vomiting and at least one of the
following: apnea, cyanosis, characteristic cough
with whooping, subconjunctival bleeding, or
leukocytosis. From 1988 to April 1997, laboratory
confirmation was defined as either a positive
culture of B. pertussis (or B. parapertussis) or
positive two-point serology, in turn defined as a
significant rise of immunoglobulin (Ig) G
antibodies against pertussis toxin or IgA
antibodies against B. pertussis in paired sera. In
April 1997, a positive polymerase chain reaction
(PCR) and positive one-point serology were also
accepted as laboratory confirmation. Positive
one-point serology was defined as high IgG or IgA
antibody titers in a single serum sample.
From 1976 to 1988, only aggregated data
were available on the total number of patients per
year. These data included case-reporting date,
number of vaccinated (at least three vaccina-
tions) and unvaccinated or incompletely vacci-
nated patients, and number of patients with
unknown vaccination status, with age at the time
of report, by age-group (<1, 1-4, 5-9, and ≥ 10
years). From 1989 to 1992, the age (in years) and
date of reporting were available for individual
patients, while the aggregated data on vaccina-
tion status were similar to those of 1976 to 1988.
Since 1993, the date of onset of symptoms, date of
birth, age in years at the time of reporting,
vaccination status, method of laboratory diagno-
sis, and contact with a person with laboratory-
confirmed pertussis were included in the
database. The method of laboratory diagnosis
was differentiated as “microbiologic” (positive
culture or PCR), “serologic,” “epidemiologic” (i.e.,
contact with a patient with laboratory-confirmed
pertussis), and “unknown.”
The case distribution from 1976 to 1988 could
only be assessed by date of reporting. From 1989
to 1992, the date of onset of symptoms was
estimated by finding the median duration
between date of first symptoms and date of
reporting (1993 to 1994). This median duration
(81 days) was then subtracted from the reporting
date of the case at hand. The distribution of cases
in 1989 to 1992 was based on this estimate, and
age distribution was based on age at the time of
reporting. For 1993 to September 1998, the
distribution of cases was based on the date of first
symptoms available in the database, and the age
distribution was based on age at onset of
symptoms.
Hospitalizations and Deaths
The number of hospitalizations with pertus-
sis as the main diagnosis (ICD-9-CM 033) in 1976
to 1997 was obtained from the registry of the
Foundation Information Center for Health Care.
For 1989 to 1997, data were available by age
group (<1, 1-4, 5-9, 10-14, 15-19, ≥ 20 years). The
number of deaths (by age, in 5-year increments)
caused by pertussis in 1976 to 1997 was obtained
from the Central Bureau of Statistics.
Serology
Data on pertussis serology were obtained
from the National Institute of Public Health and
the Environment, the only laboratory in the
Netherlands that performed serologic tests for
suspected-pertussis patients from 1982 through
January l, 1998. Other laboratories have
performed an estimated 10% to 15% of serologic
tests since 1998.
Serologic testing consisted of measuring IgA
antibodies against a crude cell-wall preparation
of  B. pertussis (available since 1981) and IgG
antibodies against purified pertussis toxin
(available since 1984) in enzyme-linked immun-
osorbent assays, according to described methods
that have not changed (10,11). The potency of the
used reference sera was stable. Serologic
interpretations have varied over the years. In
1982 to 1988, mostly single serum specimens
were submitted. Since vaccination with the
Dutch whole-cell vaccine only induces low levels
of IgG against pertussis toxin (IgG-PT) and no
IgA against B. pertussis (IgA-Bp), detection of
IgA-Bp (sonicated mixture of the two strains
included in the Dutch whole-cell vaccine) or
moderate, high, or very high IgG-PT was
reported as supportive of pertussis.
By 1987, it became clear that low and
moderate IgG-PT and IgA-Bp levels were presentResearch
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1Vaccine effectiveness = 1 – (proportion of vaccinated cases/1 – proportion of vaccinated cases) X (1 – proportion vaccinated in
the population/proportion vaccinated in the population).
in a large proportion of the population and that
the prevalence increased with age. Therefore, in
1988, serologic interpretation of single serum
specimens was abandoned, and only significant
increase of IgG-PT or IgA-Bp in paired sera was
considered confirmation of pertussis. The same
year, a strict case definition for pertussis
reporting was introduced, which included
“positive two-point serology” in the laboratory-
confirmation criteria. However, in 1993, when
serum specimens from the population, vaccinees,
and pertussis patients were tested, high IgG-PT
or high IgA-Bp levels (greater than an age-
specific cut-off value) were found to be very rare
in the population (<2.5%). Such levels were not
induced by vaccination, were present in at least
90% of patients with PCR- or culture-confirmed
pertussis, and decreased again within 6 months
to levels below the cut-off value (12-14). Since
1994, the laboratory-reported detection of such
high values in one or both samples of a serum pair
indicates “possible pertussis,” although the case
definition for reporting remained unchanged.
From April 1997, the detection of such high levels
in patients’ samples was formally defined as
“positive one-point serology” and was included in
the case definition for reporting as laboratory-
confirmed pertussis.
From the serologic database, we retrieved
data on patients whose date of disease onset was
January 1989 to September 1998 and for patients
whose date of serologic result was January 1986
to December 1987. Patients with positive two-
point serology in 1989 to 1998 and patients with
positive one-point serology in 1994 to 1998 were
selected. The criteria we recently defined for
positive one-point serology were retrospectively
applied to the serologic data of 1986–1987 and
1989–1993. The distribution of cases in 1986 and
1987 was calculated based on the year of the test
result and, in 1989–1998, based on the year of
first symptoms.
Data Analysis
We used Epi-Info version 6.04 to estimate
vaccine effectiveness1 in persons ages 1 to 4 and 5
to 9 years (reporting data from 1976 to 1997),
assuming an average vaccine coverage in the
Dutch population of 96%. We compared com-
pletely vaccinated persons (at least three
vaccinations) with incompletely vaccinated or
unvaccinated persons (15).
Since positive serologic results are included
in the case definition for reporting, the
serodiagnosis and reported-case databases are
not independent sources. For 1993 to 1997, the
reported-case database and the database with
records of serodiagnosis were linked at the
individual-patient level to verify the type of
serodiagnosis (positive two-point or positive one-
point serology) on which the reporting was based.
The completeness of the reported-case database
was calculated from the proportions of reported
patients with positive two-point and one-point
serologic results. We used the statistical package
SAS to analyze the data.
Results
Reported Cases, Hospitalizations, and
Deaths, 1976 to September 1998
In the first years of mandatory reporting of
pertussis cases, the case count was the lowest
(Table 1). From 1983 to 1987, after immunoas-
says for pertussis serology became available, the
number of reported cases increased yearly. In
1988, the year in which a case definition was
introduced and positive serology was restricted
to an increase in titer in paired sera, the number
of reported cases declined sharply. Somewhat
greater numbers of cases were reported in
1989-90 and 1993-94. In 1996, the number of
cases was 12 times higher than in 1995, while a
twofold decrease from the 1996 number was
observed in 1997.
The number of reported cases from January
to September 1998 (n = 1,582) was lower than
that of the same periods in 1996 (n = 2,171) and
1997 (n = 2,004) but approximately six times
higher than the average number of reported cases
in the same months of 1989 to 1995 (n = 269).
The trend of hospitalizations was similar to
that of case reports; however, the ratios varied by
period (Table 1). This ratio was below one from
1976 to 1984, increased to 5.7 in 1987, and
decreased sharply to 1.2 in 1988; it remained
relatively stable from 1989 to 1995 but increased
to 8.2 in 1996 and 6.1 in 1997.
From 1976 to 1997, seven deaths caused by
pertussis were reported: one in 1981, two in
1993, two in 1996, and two in 1997. They
occurred among children <1 year of age, except
for one death in 1993, which occurred in the 5-
to 9-year age group. According to the number ofResearch
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Table 1. Reported cases, hospitalizations, ratios of reported cases to hospitalizations, positive 2-point serology and
positive 1-point serology, 1976–1998
Ratio of Ratio of Ratio of
Pos. 2-point Pos. 1-point reports/ reports/pos. reports/pos.
Yr Reports Hosps test test hosps 2-point test 1-point test
1976a        4   52    NA    NA 0.1 NA NA
1977      25   93    NA    NA 0.3 NA NA
1978        1   32    NA    NA 0.0 NA NA
1979      26   43    NA    NA 0.6 NA NA
1980      30   65    NA    NA 0.5 NA NA
1981b      50   76    NA    NA 0.7 NA NA
1982      80   98    NA    NA 0.8 NA NA
1983    200 223    NA    NA 0.9 NA NA
1984c    534 200    NA    NA 2.7 NA NA
1985 1,522 313    NA    NA 4.9 NA NA
1986 2,159 388    NA 2,717 5.6 NA 0.8
1987 2,709 474    NA 3,295 5.7 NA 0.8
1988d    112   92    NA    NA 1.2 NA NA
1989    523 221    350 1,760 2.4 1.5 0.3
1990    397 157    278 1,204 2.5 1.4 0.3
1991    145   82    110    411 1.8 1.3 0.4
1992    160 101    238    861 1.6 0.7 0.2
1993    346 288    482 1,489 1.2 0.7 0.2
1994    519 276    498 1,867 1.9 1.0 0.3
1995    341 162    272 1,070 2.1 1.3 0.3
1996 4,231 513 1,885 7,854 8.2 2.2 0.5
1997e 2,671 436    924 4,107 6.1 2.9 0.7
1998f 1,582  NA    294 2,187 NA 5.4 0.7
aMandatory case reporting introduced.
bIgA assay introduced.
cIgG assay introduced.
dCase definition for reporting (including strict criteria for interpretation of serologic tests) introduced.
eFormal acceptance of positive one-point serologic test.
fData from January to September 1998.
1-point test = cases with one-point serology; 2-point test = cases with two-point serology; NA=not available.
hospitalizations among children <1 year of age,
the case-fatality rates amounted to 0.1% on
average in 1989 to 1995, 0.6% in 1996, and 0.7%
in 1997.
Serologic Results
The cases with positive one-point serology
followed a trend similar to that of cases reported
in 1986 to 1987 and 1989 to 1998 (Table 1). In
1986 and 1987, the ratio of reported cases to cases
with positive one-point serology was highest
(0.8); it decreased in 1989, and remained
relatively stable from 1989 to 1996 (0.2 to 0.4). In
1996 to 1998, this proportion increased from 0.5
to 0.7.
The trends of cases with positive two-point
serology and reported cases were similar
(Table 1). From 1989 to 1995, the number of cases
in each database was similar (ratio 0.7 to 1.5); in
1996 and 1997 (ratio 2.2 and 2.9) and particularly
in 1998 (ratio 5.4), the number of reported cases
was higher than the number of cases with
positive two-point serology.
Age-Specific Incidence, from Case Reporting
and Hospitalizations, 1989–1997
In 1989 to 1995, the average annual incidence
from case reporting was highest for infants <1
year of age. Such data for 1993 to 1995 show that
the age-specific peak incidence occurred among  ≤
5-month-old infants. For infants <1 year of age,
the incidence in 1996 was four times higher than
the average incidence from 1989 to 1995 and 13
times higher than the incidence for older age
groups (Figure 1). The age-specific peak incidence
shifted to 4-year-old children in 1996 and 1997.
From 1993 to 1997, when the method of
laboratory diagnosis was available for reported
cases, similar shifts in age distribution were
observed for cases confirmed by microbiologicResearch
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Figure 1. Average annual age-specific incidence
(number per 100,000) in 1989 through 1995, in 1996,
and in 1997.
Figure 2. Reported
pertussis cases, cases
with positive two-
point serology, and
cases with positive
one-point serology,
per month, 1989–
1998.
method (i.e., culture or PCR), cases with positive
two-point serology, and cases with positive one-
point serology. However, reported cases con-
firmed microbiologically were those of the
youngest patients; cases confirmed with one-
point serology were those of the oldest patients.
In contrast to reported cases, the greatest age-
specific incidence of hospitalizations occurred
among infants <1 year of age from 1989 to 1997
(Figure 1). The increase in incidence in 1996 was
more stable for the various age groups.
Age-Specific Incidence, from
Serologic Results, 1989-1997
As in case reports, because of a relatively
greater increase of pertussis among older age
groups, the peak incidence among cases with
positive two-point serology occurred among ≤ 5-
month-old infants from 1989 to 1995 and among
4-year-old children in 1996 and 1997. The
incidence of cases with positive one-point
serology was greatest among 7-year-old children
in 1989 and shifted towards 4-year-old children
from 1992 to 1997. As with case reports, the
increase for infants <1 year old was smaller
(fourfold) than that for older age groups (fivefold
to sevenfold) (Figure 1).
Seasonal Trend
In March and April 1996, reported cases
started to increase (Figure 2). The largest
monthly number of cases occurred later in the
year (October 1996) than in 1989-1995 and 1997-Research
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Table 2. Reported cases according to vaccination status
and estimate of vaccine-effectiveness according to
method of diagnosis
1- to 5- to
4-yr- Vaccine 9-yr- Vaccine
Method of olds efficacy olds efficacy
Yr. diagnosis (no.)    (%)a (no.)    (%)a
1993 Microbiologic      14 93      14 94
2-point serology      25 91      28 75
1-point serology      24 79      26 50
Otherb      35 96      20 90
Total      98 93      88 84
1994 Microbiologic      23 56      15 42
2-point serology      36 67      36 83
1-point serology      63 71      65  c
Otherb      37 89      29 91
Total    159 77    145 72
1995 Microbiologic      14 85        9 67
2-point serology      27 82      19 64
1-point serology      39 64      45  c
Otherb      37 53      27 67
Total    117 72    100 45
1996 Microbiologic    116 67    123   3
2-point serology    245  c    288 49
1-point serology    545  c    782  c
Otherb    290 66    355 40
Total 1,196 34 1,548 16
1997 Microbiologic      63 51      68 57
2-point serology    110  c    131  c
1-point serology    283  c    345  c
Otherb    244  c    260  c
Total    700  c    804  c
aEstimated vaccine effectiveness; a vaccine coverage of 96%
was used to estimate the incidence and vaccine effectiveness.
bEpidemiologic, serologic (differentiation between positive
two-point serology and positive one-point serology not
possible), clinical, or method of diagnosis unknown.
cVaccine effectiveness could not be estimated as the
percentage vaccinated was more than 96%.
Figure 3. Method of diagnosis for reported pertussis
cases from 1993 through 1997.
1998 (mostly in August, sometimes in July or
September). The seasonal trend of positive two-
point serology and positive one-point serology
was similar to that of case reports (Figure 2).
Vaccination Status of Reported Cases
According to case reports, vaccine effective-
ness was high in 1981 to 1984 (1 to 4 years of age:
94% to 99%; 5 to 9 years of age: 87% to 100%) and
in 1988 to 1993 (1 to 4 years of age: 89% to 95%; 5
to 9 years of age: 78% to 89%). The estimates were
somewhat lower in 1985 to 1987 (72% to 85% for
children 1 to 4 years of age and 56% to 77% for
children 5 to 9 years of age). The estimates
decreased after 1993 (Table 2), were lowest in
1996, and could not be determined in 1997 since the
proportion of vaccinated patients exceeded 96%.
Vaccine effectiveness for almost all methods
of diagnosis was greater in 1993 than in 1994 to
1997 (Table 2). The decreasing trend was not
consistent with all methods of diagnosis.
Estimates for cases diagnosed microbiologically
tended to be the highest; estimates for cases
confirmed by one-point serology tended to be the
lowest.
Method of Diagnosis for Case
Reports, 1993–1997
Linkage of the case-report and serodiagnosis
databases for 1993 to 1997 showed that the
proportion of reported cases confirmed microbio-
logically, epidemiologically, or by two-point
serology, decreased, while the proportion of cases
confirmed with positive one-point serology
increased (Figure 3). The proportion of cases
confirmed serologically but not matched with the
serologic database also increased. Differentiat-
ing these cases by positive one-point and positive
two-point serology was not possible. During 1996
and 1997, the proportion of cases confirmed
microbiologically by quarter year was similar
(8.7% to 10.2%), except for a smaller proportion
(6.4%) in the last quarter of 1997. The proportion
of cases confirmed by two-point serology was 12%
to 19%. In the first two quarters of 1996 (34.9% to
35.6%) and in the fourth quarter of 1997 (34.3%),
the proportion of cases confirmed by positive one-
point serology was similar to the proportions for
1994 and 1995. The numbers increased to >50%
in the fourth quarter of 1996 and the first quarter
of 1997. The proportion of cases confirmed
serologically that could not be matched with the
serodiagnostic database was highest (35.3%) in
the fourth quarter of 1997.Research
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Estimated Rate of Case Reporting
The reported proportion of cases with
positive two-point serology increased from 24% in
1993 to 26% in 1994, 28% in 1995, and 42%-43% in
1996 and 1997. A similar trend was observed for
the various age groups. For positive one-point
serology, the reported proportion increased from
6% in 1993, to 10% in 1994, 12% in 1995, and 27%
to 29% in 1996 and 1997. The discrepancy was
somewhat greater with increasing age. The
increase in the reported proportions of cases with
positive two-point and one-point serology was
probably underestimated because the database
of reported cases contained serologically con-
firmed cases that could not be matched with the
serodiagnosis database. This proportion was
highest in 1997 (Figure 3).
Discussion
The 1996 surveillance data show that the
unexpected pertussis outbreak was detected not
only by increased reporting of cases (5) but also by
increased hospitalizations, cases with positive
serology, and deaths. Vaccine effectiveness,
which had already declined in 1994 and 1995,
declined further in 1996 and 1997. According to
case reports and serologic data, in 1996 the
increase in pertussis incidence among (mostly
unvaccinated) children <1 year of age was similar
to the increase in hospitalizations. However, in
older, mostly vaccinated persons the increase in
hospitalizations was relatively small. Contrary to
reports at the time, a somewhat smaller epidemic
likely occurred in 1986 and 1987 (16,17).
The surveillance data for pertussis in the
Netherlands were affected by changes in
availability and interpretation of serologic tests,
case definitions for reporting, and case-reporting
rate. However, by relying on various surveillance
sources, applying criteria for one-point serology
used in recent years to serologic data of 1986 and
1987, and matching our database of reported
cases with our serodiagnosis database, we gained
a better understanding about whether observed
changes in surveillance data represented true
changes in the underlying incidence of pertussis.
The trend in hospitalizations likely reflects
the incidence of severe pertussis; however, this
trend is probably less sensitive to changes in
availability and interpretation of serologic
tests, case definitions, and case-reporting rate.
Thus, increasing or decreasing reports of
pertussis case and data on positive serology are
likely to (at least partially) reflect true changes
when they are accompanied by similar trends in
hospitalizations.
We obtained more insight into the effect of
changes in definitions of positive serology and
case definitions for reporting on serologic and
reported data. The current, more restrictive,
criteria for positivity of one-point serology were
applied to serodiagnostic data of 1986 and 1987.
It was possible to study changes in the rate of
reported cases with positive one-point serology
and cases with positive two-point serology in
1993 to 1997 by linking the case-reporting and
serodiagnosis databases. Furthermore, stratify-
ing case reports according to method of diagnosis
led us to conclude that the decrease in estimated
vaccine effectiveness and the shift in 1996 and
1997 toward older age groups in the reported
cases could only partly be explained by the
enhanced application of positive one-point serology.
Because of great variation in case definitions and
types of laboratory confirmation, comparing
numbers of reported cases in different countries
is meaningless. Hospitalizations, although lim-
ited to severe pertussis cases, might be more
useful for such international comparisons.
Our results clearly show that pertussis has
remained endemic with epidemic peaks in the
Netherlands, despite high vaccination coverage.
Immunity after infection, as well as after
vaccination, is not lifelong. Waning vaccine-
induced immunity has been suggested as an
explanation for the reemergence of the disease in
other countries and probably has contributed to
the pertussis epidemic in the 1980s and in 1996-
97 (18-20). However, the outbreak in 1986-87
may also have been associated with the Dutch
vaccine’s temporary reduction in potency—from
16 to 10 opacity units per dose—in 1976 to 1984.
The somewhat lower vaccine-effectiveness esti-
mates in 1986 and 1987 might be explained by
greater exposure to B. pertussis in epidemics
than in interepidemic periods (21,22).
The remarkable increase in reported cases
among vaccinated patients over a wide age range,
starting 2 years before the 1996 outbreak,
suggests a mismatch between circulating strains
and vaccine strains (5,7-9). Antigenic divergence
between vaccine strains and clinical isolates was
observed for two important protective anti-
gens, pertactin and pertussis toxin (9).
Furthermore, data suggest that the whole-cell
vaccine protects better against strains with theResearch
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pertactin vaccine type than against strains with
nonvaccine types (9).
By analyzing serologic and hospitalization
data apart from case-reporting data, we assessed
the increase in pertussis incidence in 1996 among
(mostly unvaccinated) children <1 year of age.
The increase in incidence was accompanied by
a similar increase in hospitalizations for
pertussis in the same age group, which
indicates that the virulence of B. pertussis for
unvaccinated and unexposed persons did not
change during the outbreak.
In contrast, for older, mostly vaccinated
persons, the increase in hospitalizations was
smaller than the increase found in other
surveillance sources. While the incidence of
hospital admissions was highest for infants <1
year of age, the incidence in other surveillance
sources was highest in 4-year-old children.
Therefore, a greater proportion of infected
vaccinated persons may have had clinical
symptoms because of antigenic shifts, which
probably led to greater transmission of bacteria
and thus a greater degree of infection in the
population. This is shown by the increase of cases
in unvaccinated infants.
Despite the findings of antigenic variants of
pertactin and pertussis toxin in other countries,
no outbreaks similar to those in the Netherlands
have been observed (23-25). The vaccines in these
countries may be potent enough to offset
antigenic variation, or pertussis vaccines may
protect less well against strains with pertactin
profiles dominant in the Netherlands but less
common elsewhere (23). The Dutch vaccine has
been used in the National Immunization
Program since 1953. No sign of an abrupt
deterioration of vaccine quality, as determined
for product release by the mouse protection test,
has been found (5). However, the Dutch whole-
cell vaccine induces low levels of antibodies
against pertussis toxin and filamentous hemag-
glutinin and high levels of antibodies to
agglutinogens and pertactin (6). This immunoge-
nicity profile may have resulted in a greater
vulnerability of the vaccinated Dutch population
to antigenic changes in B. pertussis, especially
with respect to pertactin. Since November 1997,
the production process for the Dutch pertussis
vaccine has been improved, resulting in a slightly
higher expression of pertussis toxin. We have not
yet studied the potential effect of this change.
Pertussis is also reemerging in Canada,
where similar surveillance patterns may eluci-
date the role of the vaccine’s immunogenicity
profile (1,2,5). These similarities are the small
proportion of infants and large proportion of
patients 1 to 9 years of age affected, estimates of
low vaccine effectiveness, and lower levels of
antibodies against pertussis toxin after vaccina-
tion with the Canadian whole-cell vaccine
(20,26). By contrast, the increase in pertussis
cases in the United States is accompanied by
greater proportions of affected infants and adults
and more favorable vaccine-effectiveness esti-
mates (22,27,28). The levels of pertussis toxin
antibodies after vaccination were higher for an
American whole-cell vaccine than for Canadian
whole-cell vaccines (26).
Conclusions
The surveillance data support, even if they do
not definitively explain, the hypothetical role of
antigenic changes in B. pertussis during the 1996
pertussis outbreak in the Netherlands. The
indisputable role of whole-cell vaccine in
protecting against severe pertussis is clearly
shown by the sharp decrease in hospitalizations
among children >12 months of age; this
protection is also shown by a much smaller
pertussis incidence (in the past and at present) in
the Netherlands than in countries with large
unvaccinated populations (29). In such countries,
60% of unvaccinated persons have clinical
pertussis before the age of 10. This incidence is at
least 30 times higher than that in the
Netherlands, even if we assume a case-reporting
rate of 25% and an incidence similar to that
observed during the Dutch epidemic in 1996.
Booster vaccination will be helpful in
reducing the incidence of pertussis. However,
some acellular vaccines do not contain the
antigenic variants of pertactin and pertussis
toxin that dominate in Europe (9,23,24).
Furthermore, if pertussis infections are to be
postponed until adulthood as a result of boosting,
the probability of transmission from adults to
young, unvaccinated infants might be greater.
The effects of booster vaccination on the
epidemiology of pertussis must be monitored
carefully, and various surveillance sources must
be used to distinguish surveillance artifacts and
real epidemiologic effects.Research
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